In this Science Friday interview, Dr. Carl June discusses CAR-T's continued use in battling new blood cancers, as well as its future potential for treating solid state cancers and autoimmune diseases.
"We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me."
Penn Spinout REGENXBIO Inc. Enters Commercial Phase; Focuses Gene Therapy on Common Cause of Blindness
Regenxbio's gene therapy would eliminate the need for wet AMD patients to visit their doctor every few months to receive a needle in their eye to treat their condition.
Three Penn Medicine Innovation Projects Receive Clinical Care Innovation Grants from Independence Blue Cross
Learn about these cutting-edge new projects that are improving value-based medical care.
Penn Medicine ranked number two out of the top five large health systems, second only to Mayo Clinic in Rochester, MN.
Philadelphia-based Cancer Research Institutions Receive over $700M in National Cancer Institute Grants from 2019 to 2021, Fourth-most in the Nation
The University of Pennsylvania led the region with 490 NCI grants totaling $234 million during this three year time period.
Penn spinout Verismo Therapeutics Makes Agreement to Fund University Research of KIR-CAR platform of Car-T to Target Solid Tumors
Learn about Penn spinout Verismo Therapeutics' agreement to fund four years of university research of KIR-CAR platform of Car-T to target solid tumors.
Learn about Dr. Bruce Levine's predictions for the future uses of Car-T therapy.
Gnubiotics and Penn to Explore Car-T Therapy in Combination with Glycopeptides to Target Solid Tumors
This collaboration will take place through company-sponsored pre-clinical research studies in the laboratory of Avery Posey, PhD, an assistant professor at the Perelman School of Medicine.
Five years after Penn and Novartis made history with the FDA approval of Kymriah, a recent study shows the long-term impact of the medication on patient remission rates.